Actemra poised to launch IL-6 inhibitors
L Melton, A Coombs - Nature Biotechnology, 2008 - go.gale.com
L Melton, A Coombs
Nature Biotechnology, 2008•go.gale.comNews that a US Food and Drug Administration expert panel backed Roche's Actemra
(tocilizumab) with a near unanimous vote triggered analysts' talk of blockbuster revenues for
the Basel-based Swiss company. Should the agency approve this closely watched
humanized monoclonal antibody (mAb) targeting interleukin-6 (IL-6) receptor for rheumatoid
arthritis, the novel class of anti-inflammatory drugs could shake up the biologics market in
chronic inflammatory diseases, which has been dominated by tumor necrosis factor (TNF) …
(tocilizumab) with a near unanimous vote triggered analysts' talk of blockbuster revenues for
the Basel-based Swiss company. Should the agency approve this closely watched
humanized monoclonal antibody (mAb) targeting interleukin-6 (IL-6) receptor for rheumatoid
arthritis, the novel class of anti-inflammatory drugs could shake up the biologics market in
chronic inflammatory diseases, which has been dominated by tumor necrosis factor (TNF) …
News that a US Food and Drug Administration expert panel backed Roche's Actemra (tocilizumab) with a near unanimous vote triggered analysts' talk of blockbuster revenues for the Basel-based Swiss company. Should the agency approve this closely watched humanized monoclonal antibody (mAb) targeting interleukin-6 (IL-6) receptor for rheumatoid arthritis, the novel class of anti-inflammatory drugs could shake up the biologics market in chronic inflammatory diseases, which has been dominated by tumor necrosis factor (TNF)-?? inhibitors. But with several other firms moving IL-6 blockers through their pipelines and watching Actemra's
Gale